Advances in Targeting HER3 as an Anticancer Therapy. (7th November 2012)

• Record Type: Journal Article
• Authors: Jiang, Ning; Saba, Nabil F.; Chen, Zhuo Georgia
• Other Names: Haigentz Missak Academic Editor.
• Is Part Of: Chemotherapy research and practice. Volume 2012(2012)
• Publication Date: 2012-11-07
• Subjects: Chemotherapy -- Periodicals; Drug Therapy; Pharmaceutical Preparations; Chemotherapy; Electronic journals; Periodical; Periodicals; Fulltext; Internet Resources; Periodicals; 615.58
• DOI: 10.1155/2012/817304
• Languages: English
• ISSNs: 2090-2107

Abstract

Abstract : HER3 (ErbB3) is a unique member of the human epidermal growth factor receptor (EGFR) family (ErbB family). It functions only through dimerization with other members of the ErbB family and modulates activity and sensitivity to targeted cancer therapies. This paper briefly describes the mechanism of HER3 in signal transduction and its potential role in acquired resistance to EGFR- and HER2-targeted therapies. We also consider recent developments in HER3-targeting therapeutics and their combination with inhibitors of other ErbB members in clinical applications.